UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis

Journal of clinical gastroenterology, 2020-11, Vol.54 (10), p.911-911

Modesto, Irene

2020

Volltextzugriff (PDF)

Mesalazine for the treatment of inflammatory bowel disease

Expert opinion on pharmacotherapy, 2013-08, Vol.14 (12), p.1669-1678

2013

Volltextzugriff (PDF)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis

Therapeutic advances in gastroenterology, 2021, Vol.14, p.17562848211005708-17562848211005708

2021

Volltextzugriff (PDF)

Is 5-ASA still the treatment of choice for ulcerative colitis?

Current drug targets, 2011-09, Vol.12 (10), p.1396-1405

2011

Volltextzugriff (PDF)

Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies

Therapeutic advances in gastroenterology, 2021-11, Vol.14, p.17562848211054710-17562848211054710

2021

Volltextzugriff (PDF)

Methodology for high-quality studies on course and prognosis of inflammatory bowel disease

World journal of gastroenterology : WJG, 2012-08, Vol.18 (29), p.3800-3805

2012

Volltextzugriff (PDF)

Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use

Inflammatory intestinal diseases, 2021-12, Vol.6 (4), p.186-198

2021

Volltextzugriff (PDF)

Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis

BMJ open gastroenterology, 2020-09, Vol.7 (1), p.e000456

2020

Volltextzugriff (PDF)

Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy

Microorganisms (Basel), 2020-11, Vol.8 (11), p.1792

2020

Volltextzugriff (PDF)

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance

Annals of the rheumatic diseases, 2023-07, Vol.82 (7), p.901-910

2023

Volltextzugriff (PDF)

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme

Alimentary pharmacology & therapeutics, 2019-11, Vol.50 (10), p.1068-1076

2019

Volltextzugriff (PDF)

Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status

Clinical gastroenterology and hepatology, 2022-03, Vol.20 (3), p.591-601.e8

2022

Volltextzugriff (PDF)

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment

Alimentary pharmacology & therapeutics, 2022-02, Vol.55 (4), p.464-478

2022

Volltextzugriff (PDF)

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry

Inflammatory bowel diseases, 2021-04, Vol.27 (4), p.585-589

2021

Volltextzugriff (PDF)

The Role of Portal Vein Thrombosis in the Clinical Course of Inflammatory Bowel Diseases : Report on Three Cases and Review of the Literature

Gastroenterology research and practice, 2012-01, Vol.2012 (2012), p.1-7

2012

Volltextzugriff (PDF)

Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments

Gut, 2021-02, Vol.70 (2), p.418-426

2021

Volltextzugriff (PDF)

Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review

Expert review of gastroenterology & hepatology, 2021-09, Vol.15 (9), p.985-997

2021

Volltextzugriff (PDF)

Tu1735 TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG TWICE DAILY (BID) VS REMAINING ON 10 MG BID IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION ON 10 MG BID: UPDATED 30 MONTH DATA FROM THE DOUBLE-BLIND, RANDOMIZED RIVETING STUDY

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-1101-S-1102

2023

Volltextzugriff (PDF)

Tu1719 ACHIEVEMENT OF STRINGENT HISTOLOGIC AND COMPOSITE ENDPOINTS IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-1092-S-1093

2023

Volltextzugriff (PDF)

Tu1869 TIME TO LOSS OF EFFICACY AMONG PATIENTS IN REMISSION FOLLOWING INDUCTION TREATMENT WITH TOFACITINIB 10 MG BID WHO REDUCED TOFACITINIB DOSE OR DISCONTINUED TOFACITINIB IN OCTAVE SUSTAIN

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-1196-S-1196

2020

Volltextzugriff (PDF)

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis

Alimentary pharmacology & therapeutics, 2022-02, Vol.55 (3), p.302-310

2022

Volltextzugriff (PDF)

S924 Cardiovascular Outcome and Cancer Risk in Adult Patients With Ulcerative Colitis in Routine Clinical Care: The Effect of Cardiovascular Risk-Enrichment Factors

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e670-e671

2022

Volltextzugriff (PDF)

Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod

Clinical gastroenterology and hepatology, 2024-07

2024

Volltextzugriff (PDF)

Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial

Journal of Crohn's and colitis, 2021-07, Vol.15 (7), p.1130-1141

2021

Volltextzugriff (PDF)

Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis

Digestive diseases and sciences, 2023-06, Vol.68 (6), p.2624-2634

2023

Volltextzugriff (PDF)

1 – 25 von 91

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(90)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis

Mesalazine for the treatment of inflammatory bowel disease

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis

Is 5-ASA still the treatment of choice for ulcerative colitis?

Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies

Methodology for high-quality studies on course and prognosis of inflammatory bowel disease

Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use

Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis

Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme

Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry

The Role of Portal Vein Thrombosis in the Clinical Course of Inflammatory Bowel Diseases : Report on Three Cases and Review of the Literature

Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments

Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review

Tu1735 TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG TWICE DAILY (BID) VS REMAINING ON 10 MG BID IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION ON 10 MG BID: UPDATED 30 MONTH DATA FROM THE DOUBLE-BLIND, RANDOMIZED RIVETING STUDY

Tu1719 ACHIEVEMENT OF STRINGENT HISTOLOGIC AND COMPOSITE ENDPOINTS IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Tu1869 TIME TO LOSS OF EFFICACY AMONG PATIENTS IN REMISSION FOLLOWING INDUCTION TREATMENT WITH TOFACITINIB 10 MG BID WHO REDUCED TOFACITINIB DOSE OR DISCONTINUED TOFACITINIB IN OCTAVE SUSTAIN

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis

S924 Cardiovascular Outcome and Cancer Risk in Adult Patients With Ulcerative Colitis in Routine Clinical Care: The Effect of Cardiovascular Risk-Enrichment Factors

Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod

Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial

Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis

Suchergebnisse filtern